Clearside Biomedical Inc (CLSD)
1.31
-0.01
(-0.76%)
USD |
NASDAQ |
May 03, 16:00
1.32
+0.01
(+0.76%)
After-Hours: 20:00
Clearside Biomedical Enterprise Value: 68.96M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 68.96M |
| May 02, 2024 | 69.71M |
| May 01, 2024 | 65.98M |
| April 30, 2024 | 65.23M |
| April 29, 2024 | 67.47M |
| April 26, 2024 | 71.21M |
| April 25, 2024 | 65.23M |
| April 24, 2024 | 71.21M |
| April 23, 2024 | 73.45M |
| April 22, 2024 | 76.44M |
| April 19, 2024 | 68.96M |
| April 18, 2024 | 69.71M |
| April 17, 2024 | 65.23M |
| April 16, 2024 | 57.01M |
| April 15, 2024 | 67.47M |
| April 12, 2024 | 64.48M |
| April 11, 2024 | 68.22M |
| April 10, 2024 | 63.73M |
| April 09, 2024 | 67.47M |
| April 08, 2024 | 67.47M |
| April 05, 2024 | 68.22M |
| April 04, 2024 | 70.46M |
| April 03, 2024 | 77.93M |
| April 02, 2024 | 75.69M |
| April 01, 2024 | 89.14M |
| Date | Value |
|---|---|
| March 28, 2024 | 85.40M |
| March 27, 2024 | 95.86M |
| March 26, 2024 | 97.36M |
| March 25, 2024 | 100.35M |
| March 22, 2024 | 98.85M |
| March 21, 2024 | 105.58M |
| March 20, 2024 | 92.88M |
| March 19, 2024 | 92.88M |
| March 18, 2024 | 87.64M |
| March 15, 2024 | 98.85M |
| March 14, 2024 | 100.35M |
| March 13, 2024 | 92.88M |
| March 12, 2024 | 93.62M |
| March 11, 2024 | 122.02M |
| March 08, 2024 | 95.86M |
| March 07, 2024 | 95.86M |
| March 06, 2024 | 83.91M |
| March 05, 2024 | 74.94M |
| March 04, 2024 | 74.94M |
| March 01, 2024 | 74.94M |
| February 29, 2024 | 75.69M |
| February 28, 2024 | 76.44M |
| February 27, 2024 | 75.32M |
| February 26, 2024 | 71.21M |
| February 23, 2024 | 72.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.045M
Minimum
Sep 03 2019
401.84M
Maximum
Aug 27 2021
85.21M
Average
61.46M
Median
Aug 12 2020
Enterprise Value Benchmarks
| Cassava Sciences Inc | 831.98M |
| Heron Therapeutics Inc | 485.70M |
| Actinium Pharmaceuticals Inc | 182.80M |
| Karyopharm Therapeutics Inc | 109.50M |
| Ocular Therapeutix Inc | 796.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.832M |
| Revenue (Quarterly) | 6.345M |
| Total Expenses (Quarterly) | 9.26M |
| EPS Diluted (Quarterly) | -0.08 |
| Profit Margin (Quarterly) | -76.15% |
| Earnings Yield | -40.46% |
| Normalized Earnings Yield | -40.46 |